Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban for cancer-related coagulopathy in stroke (ENCHASE)
NCT03570281Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jun 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of edoxaban in cancer-associated coagulopathy (CAC), ischemic stroke, sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
edoxaban
03
Conditions
cancer-associated coagulopathy (CAC)ischemic stroke
Beyond the preview
Go deeper on NCT03570281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570281.